KR102649644B1 - 편두통 예방을 위한 라스미디탄의 만성 야간 투여 - Google Patents

편두통 예방을 위한 라스미디탄의 만성 야간 투여 Download PDF

Info

Publication number
KR102649644B1
KR102649644B1 KR1020217005977A KR20217005977A KR102649644B1 KR 102649644 B1 KR102649644 B1 KR 102649644B1 KR 1020217005977 A KR1020217005977 A KR 1020217005977A KR 20217005977 A KR20217005977 A KR 20217005977A KR 102649644 B1 KR102649644 B1 KR 102649644B1
Authority
KR
South Korea
Prior art keywords
migraine
lasmiditan
patient
dose
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217005977A
Other languages
English (en)
Korean (ko)
Other versions
KR20210039419A (ko
Inventor
로버트 러셀 콘리
구다즈 다바
커크 윌리스 존슨
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68051892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102649644(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20210039419A publication Critical patent/KR20210039419A/ko
Application granted granted Critical
Publication of KR102649644B1 publication Critical patent/KR102649644B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
KR1020217005977A 2018-09-04 2019-09-03 편두통 예방을 위한 라스미디탄의 만성 야간 투여 Active KR102649644B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862726585P 2018-09-04 2018-09-04
US62/726,585 2018-09-04
PCT/US2019/049340 WO2020051137A1 (en) 2018-09-04 2019-09-03 Chronic nightly dosing of lasmiditan for migraine prevention

Publications (2)

Publication Number Publication Date
KR20210039419A KR20210039419A (ko) 2021-04-09
KR102649644B1 true KR102649644B1 (ko) 2024-03-21

Family

ID=68051892

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217005977A Active KR102649644B1 (ko) 2018-09-04 2019-09-03 편두통 예방을 위한 라스미디탄의 만성 야간 투여

Country Status (36)

Country Link
US (1) US12138254B2 (https=)
EP (2) EP4279132A3 (https=)
JP (2) JP7321256B2 (https=)
KR (1) KR102649644B1 (https=)
CN (1) CN112638383A (https=)
AU (3) AU2019336667B2 (https=)
BR (1) BR112021002945A2 (https=)
CL (1) CL2021000529A1 (https=)
CO (1) CO2021002766A2 (https=)
CR (1) CR20210126A (https=)
DK (1) DK3846810T3 (https=)
DO (1) DOP2021000039A (https=)
EA (1) EA202190440A1 (https=)
EC (1) ECSP21015491A (https=)
ES (1) ES2967665T3 (https=)
FI (1) FI3846810T3 (https=)
HR (1) HRP20231587T1 (https=)
HU (1) HUE064519T2 (https=)
IL (1) IL281208B2 (https=)
JO (1) JOP20210033B1 (https=)
LT (1) LT3846810T (https=)
MA (1) MA53551B1 (https=)
MD (1) MD3846810T2 (https=)
MX (1) MX2021002474A (https=)
MY (1) MY199662A (https=)
PE (1) PE20211599A1 (https=)
PH (1) PH12021550448A1 (https=)
PL (1) PL3846810T3 (https=)
PT (1) PT3846810T (https=)
RS (1) RS64857B1 (https=)
SG (1) SG11202101530PA (https=)
SI (1) SI3846810T1 (https=)
TW (1) TWI826514B (https=)
UA (1) UA129587C2 (https=)
WO (1) WO2020051137A1 (https=)
ZA (1) ZA202100666B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2413933T5 (pl) 2009-04-02 2021-10-18 Colucid Pharmaceuticals, Inc. 2,4,6-trifluoro-N-[6-(1-metylopiperydyno-4-karbonylo)pirydyn-2-ylo]benzamid do leczenia migreny drogą doustną lub dożylną
JP6491669B2 (ja) 2014-02-05 2019-03-27 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｇｒｐ活性化合物の錠剤製剤
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CN116390712A (zh) * 2020-07-29 2023-07-04 阿勒根制药国际有限公司 治疗偏头痛
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2023049920A1 (en) 2021-09-27 2023-03-30 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5385912A (en) 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5360735A (en) 1992-01-08 1994-11-01 Synaptic Pharmaceutical Corporation DNA encoding a human 5-HT1F receptor, vectors, and host cells
US5521196A (en) 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5698571A (en) 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
US5521197A (en) 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
NZ305166A (en) 1995-03-20 1998-12-23 Lilly Co Eli 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles; preparation and medicaments
US5942536A (en) 1995-10-10 1999-08-24 Eli Lilly And Company N- 2-substituted-3-(2-aminoethyl)-1H-indol-5-YL!-Amides: new 5-HT1F agonists
US5708187A (en) 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
BR9711273A (pt) 1996-08-28 1999-08-17 Lilly Co Eli 1,2,3,4- Tetraidro-2-dibenzofuranaminas substituidas e 2- aminociclohepta b benzofuranos
AU4652697A (en) 1996-10-08 1998-05-05 Eli Lilly And Company New serotonin 5-ht1f agonists
ZA979961B (en) 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
EP0875513A1 (en) 1997-04-14 1998-11-04 Eli Lilly And Company Substituted heteroaromatic 5-HT 1F agonists
ID23053A (id) 1997-06-04 2000-01-20 Lilly Co Eli Karboksamida yang digunakan sebagai agonis 5-ht <if>
US5905084A (en) 1997-11-14 1999-05-18 Eli Lilly And Company 5-HTIF -agonists effective in treating migraine
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
AU4961499A (en) 1998-06-26 2000-01-17 Eli Lilly And Company 5-HT1f agonists
JP2002519348A (ja) 1998-06-30 2002-07-02 イーライ・リリー・アンド・カンパニー ５−ｈｔ１ｆアゴニスト
US6608079B1 (en) 1998-12-11 2003-08-19 Eli Lilly And Company Indole derivatives and their use as 5-HT1F agonists
US6777428B1 (en) 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
DE60036924T2 (de) 1999-02-10 2008-08-14 Eli Lilly And Co., Indianapolis 5-ht1f agonisten
AU3354000A (en) 1999-02-26 2000-09-14 Eli Lilly And Company 5-ht1f agonists
WO2002006196A1 (en) 2000-07-13 2002-01-24 Merck Patent Gmbh Chiral compounds i
US6650463B2 (en) 2001-03-13 2003-11-18 Seiko Epson Corporation Electrophoretic display device
WO2003000245A1 (en) 2001-06-22 2003-01-03 Poseidon Pharmaceuticals A/S Compounds for use in disorders associated with mast cell or basophil activity
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
AU2003295782A1 (en) 2002-11-22 2004-06-18 Bristol-Myers Squibb Company Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
MXPA05011223A (es) 2003-04-18 2006-01-26 Lilly Co Eli Compuestos de (piperidiniloxi)fenilo, (piperidiniloxi)piridinilo, (piperidinilsulfanil)fenilo y (piperidinilsulfanil)piridinilo como agonistas 5-htif.
WO2004099127A1 (en) 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
US7915293B2 (en) 2003-05-30 2011-03-29 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
UA82711C2 (en) 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
GB0510143D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
WO2006048771A1 (en) 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
AU2005311251A1 (en) 2004-12-01 2006-06-08 Devgen Nv 5-carboxamido substituted thiazole derivatives that interact with ion channels, in particular with ion channels from the Kv family
KR20060067738A (ko) 2004-12-15 2006-06-20 주식회사 대웅제약 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 신규한 ｎ-아릴아마이드 유도체 및 이를함유하는 약제학적 조성물
US20060178349A1 (en) 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
DE102005016634A1 (de) 2005-04-12 2006-10-19 Merck Patent Gmbh Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
KR100976063B1 (ko) 2007-03-16 2010-08-17 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
PL2413933T5 (pl) * 2009-04-02 2021-10-18 Colucid Pharmaceuticals, Inc. 2,4,6-trifluoro-N-[6-(1-metylopiperydyno-4-karbonylo)pirydyn-2-ylo]benzamid do leczenia migreny drogą doustną lub dożylną
US8697876B2 (en) * 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
KR20190075130A (ko) 2016-12-06 2019-06-28 코루시드 파마슈티컬즈 인코포레이티드 피리디노일피페리딘 5-ht1f 작용제에 관한 조성물 및 방법
TWI754772B (zh) 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
New England journal of medicine, 2002, 346(4), 257-270*
The Lancet Neurology, 2012, 11(5), 405-413*

Also Published As

Publication number Publication date
PE20211599A1 (es) 2021-08-18
EP4279132A3 (en) 2024-03-06
AU2019336667A1 (en) 2021-03-11
IL281208B2 (en) 2025-02-01
SG11202101530PA (en) 2021-03-30
FI3846810T3 (fi) 2023-12-15
ECSP21015491A (es) 2021-04-29
EP4279132A2 (en) 2023-11-22
MX2021002474A (es) 2021-08-24
HUE064519T2 (hu) 2024-03-28
TW202033197A (zh) 2020-09-16
MA53551A (fr) 2022-01-12
PH12021550448A1 (en) 2021-09-27
UA129587C2 (uk) 2025-06-11
ZA202100666B (en) 2024-09-25
IL281208B1 (en) 2024-10-01
CR20210126A (es) 2021-04-22
WO2020051137A1 (en) 2020-03-12
RS64857B1 (sr) 2023-12-29
TWI826514B (zh) 2023-12-21
HRP20231587T1 (hr) 2024-03-15
IL281208A (en) 2021-04-29
PT3846810T (pt) 2023-12-14
NZ774400A (en) 2024-03-22
EP3846810B1 (en) 2023-10-18
EA202190440A1 (ru) 2021-06-24
MD3846810T2 (ro) 2024-04-30
US20210338655A1 (en) 2021-11-04
DK3846810T3 (da) 2023-12-04
JOP20210033A1 (ar) 2021-02-25
CA3111205A1 (en) 2020-03-12
EP3846810A1 (en) 2021-07-14
CN112638383A (zh) 2021-04-09
JP2021535913A (ja) 2021-12-23
JP7543497B2 (ja) 2024-09-02
AU2022291568A1 (en) 2023-02-02
AU2025201479A1 (en) 2025-03-20
BR112021002945A2 (pt) 2021-05-11
SI3846810T1 (sl) 2023-12-29
JP7321256B2 (ja) 2023-08-04
CO2021002766A2 (es) 2021-03-19
JOP20210033B1 (ar) 2024-04-18
CL2021000529A1 (es) 2021-08-13
KR20210039419A (ko) 2021-04-09
MY199662A (en) 2023-11-15
US12138254B2 (en) 2024-11-12
PL3846810T3 (pl) 2024-03-18
AU2019336667B2 (en) 2022-09-29
DOP2021000039A (es) 2021-03-31
MA53551B1 (fr) 2023-11-30
LT3846810T (lt) 2024-01-10
JP2023156344A (ja) 2023-10-24
ES2967665T3 (es) 2024-05-03

Similar Documents

Publication Publication Date Title
KR102649644B1 (ko) 편두통 예방을 위한 라스미디탄의 만성 야간 투여
Fava et al. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.
EP3340971B1 (en) Methods of treating lennox-gastaut syndrome using fenfluramine
Weddington et al. Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence
KR20200036919A (ko) 편두통의 치료에 사용하기 위한 라스미디탄 및 cgrp 길항제의 조합 요법
Pabis et al. Pharmacotherapy of aggressive behavior
EP3893876A1 (en) Deutetrabenazine for the treatment of dyskinesia in cerebral palsy
US20230201148A1 (en) Uses of ornithine phenylacetate for treating hyperammonemia
Vakhapova et al. Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety
CA3111205C (en) Chronic nightly dosing of lasmiditan for migraine prevention
HK40045255B (en) Chronic nightly dosing of lasmiditan for migraine prevention
HK40045255A (en) Chronic nightly dosing of lasmiditan for migraine prevention
EA046122B1 (ru) Длительное введение ласмидитана на ночь для профилактики мигрени
Cooper Psychopharmacology and physical treatments
Reisner et al. Reboxetine (PNU-155950E) Versus Placebo and Fluoxetine in a Controlled, Randomized, Double-Blind, Multicenter Study of Treatment in Major Depressive Disorders
Weiser et al. P. 1.042 Efficacy and tolerability of depressioninthe treatment of major depression due to Parkinson disease

Legal Events

Date Code Title Description
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601